Atai reports its Q2 2022 results, announces a new $175 million loan facility and streamlines its operations.
Mind Medicine announces a reverse share split of its common shares at a 1-15 ratio. Exchange symbols will remain the same but new CUSIP numbers will be assigned by the appropriate regulators.
Awakn Life Sciences announces UK government grant funding to cover 2/3rds of the costs of its Phase III clinical trial for alcohol use disorder (AUD).
Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.
Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland's MISTERCAP brand of psilocybin-based products.
Cybin announces receipt of its "may proceed letter" from the U.S. Food and Drug Administration (FDA) regarding its Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).
Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.
Better Life Pharma will be presenting an abstract on its lead compound, BETR-001, to the European Neuroscience Societies (FENS) Forum in July.